Class Action Sued ARS Pharmaceuticals for Securities Law Violations

LOS ANGELES, Sept. 8, 2026 /CourierPR/ -- ARS Pharmaceuticals, Inc., the pharmaceutical company listed on NASDAQ under the ticker symbol SPRY, has been the subject of a class action lawsuit filed by the DJS Law Group. The lawsuit alleges that ARS Pharmaceuticals violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaint asserts that the company made false and misleading statements to the market during a specific period.

According to the complaint, ARS Pharmaceuticals was aware of issues with its timeline for CVS Caremark formulary and coverage approval decisions for a drug called neffy. These delays were expected to impact the company's commercialization plans. The lawsuit claims that the company's public statements during the class period were therefore false and materially misleading.

The class period for the lawsuit spans from March 9, 2026, to June 24, 2026. Investors who purchased shares of SPRY during this period are encouraged to contact the DJS Law Group to discuss their potential rights. The firm specializes in securities class actions, corporate governance litigation, and M&A appraisals, and has a history of representing some of the largest and most sophisticated hedge funds and alternative asset managers in the world.

David J. Schwartz, a founding partner of Schall Brown & Schwartz LLP, leads the DJS Law Group. He focuses on enhancing investor returns through balanced counseling and aggressive advocacy. The firm has a strong track record of successfully representing clients in complex financial litigation.

The deadline for interested investors to contact the DJS Law Group for possible lead plaintiff appointments is October 5, 2026. Participation in the lawsuit is not required to potentially recover losses, but interested parties are encouraged to act before the deadline.